Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valoctocogene Roxaparvovec in Japanese Patients With Severe Hemophilia A
NCT06224907Phase 3Active, not recruiting
- Sponsor
- BioMarin Pharmaceutical
- Start
- Dec 2023
- Primary completion
- Apr 2025
- Modality
- Gene Editing, Gene Silencing, AAV Vectors
- Countries
- 1
01
Overview
A Phase 3 trial of valoctocogene roxaparvovec in hemophilia A, sponsored by BioMarin Pharmaceutical. Started Dec 2023; status: active, not recruiting.
02
Drugs
valoctocogene roxaparvovec
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT06224907.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06224907.